- UK status: Not licensed by the MHRA; not available on the NHS or by private prescription.
- US status: FDA-approved on 1 April 2026 as Foundayo.
- What it is: A once-daily oral (pill) GLP-1 receptor agonist — not an injection.
- Why it's notable: Unlike the semaglutide tablet (Rybelsus), it has no fasting or strict-timing rules.
- Buying it online now: Not safe — there is no legitimate UK supply.
What is orforglipron?
Orforglipron is a GLP-1 receptor agonist, the same broad family as Mounjaro and Wegovy, but with two differences that have generated a lot of interest. First, it is a once-daily tablet rather than a weekly injection. Second, it is a small-molecule drug (not a peptide), which means — unlike the existing oral semaglutide tablet, Rybelsus — it does not have to be taken on an empty stomach with strict timing and water rules. It is being developed both for weight management and for type 2 diabetes. Because it is not licensed in the UK, this guide does not give any dosing information.
Is it available in the UK?
No. For any medicine to be prescribed or sold in the UK it must first be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Orforglipron does not yet have that authorisation, so:
- It cannot be prescribed on the NHS.
- It cannot be legally supplied by a UK private clinic or pharmacy.
- A US FDA approval does not carry over to the UK — the MHRA runs its own independent review.
For NHS use, even after any MHRA licence, a medicine also normally needs a NICE appraisal before it is routinely funded. That is two separate steps still to come.
What did the trials show?
Eli Lilly reported results from a large phase 3 programme during 2025, which is why the drug has been in the news. In summary (these are trial-level, manufacturer-reported figures, not a promise of individual results):
| Trial | Group | Reported result |
|---|---|---|
| ATTAIN-1 (obesity) | Adults without diabetes | Average weight loss of about 12% at 72 weeks on the highest dose, versus about 1% on placebo |
| ACHIEVE-1 (type 2 diabetes) | Adults with type 2 diabetes | Average HbA1c (long-term blood sugar) reduction of roughly 1.3–1.6% at 40 weeks |
As with other GLP-1 medicines, the most common side effects were gut-related (nausea, vomiting, diarrhoea), and these were the main reason some people stopped treatment. A pooled analysis of the phase 3 programme did not find a signal of drug-induced liver injury, which had been an early question. It is worth noting there is not yet a completed cardiovascular-outcomes trial, and no head-to-head trial against injectable GLP-1 medicines — so claims that it matches injections like Mounjaro should be treated with caution.
When might it reach the UK?
There is no confirmed UK launch date. Lilly has said it submitted orforglipron to many regulators worldwide, and reviews by the MHRA and the European Medicines Agency are expected to progress through 2026, but the outcome and timing are not guaranteed. Any specific "coming to the UK in [month]" dates you see online are estimates, not official commitments. The realistic sequence is: MHRA decision first, then — for NHS funding — a NICE appraisal. We will update this page as the UK regulatory position changes.
What UK patients can do now
- Don't try to buy orforglipron online — there is no safe, legal UK source yet.
- Talk to your GP about weight management. If a medicine is appropriate, licensed options such as Wegovy and Mounjaro are available in the UK through proper routes.
- Be sceptical of hype. A pill is convenient, but "convenient" is not the same as "more effective", and the long-term UK evidence and licensing are not yet in place.
Related reading
Mounjaro (tirzepatide) in the UK
A licensed option: availability, price and access.
Wegovy & Ozempic (semaglutide)
Licensed weight-loss and diabetes options in the UK.
Do GLP-1 medicines cause muscle loss?
What the evidence says, and how to protect muscle.
We'll track orforglipron's UK status for you
MediWatch monitors UK medicine availability and licensing. Search and set up free alerts.
Search shortages free →Official & primary sources: MHRA (gov.uk) · NICE technology appraisals · NHS England: medicines for obesity · US FDA approval and Eli Lilly phase 3 (ATTAIN / ACHIEVE) announcements, 2025–2026.
MediWatch is not medical advice. Do not buy prescription medicines from unregulated sellers. Always ask a pharmacist, GP, specialist, NHS 111, or emergency services if you are unsure or unwell.